

AMENDMENTS TO THE SPECIFICATION

In the title, please replace the current title with the following:

**~~NOVEL METHODS FOR THE PRODUCTION OF ANTI-HUMAN RECEPTORS AND~~
~~USES THEREOF~~ ANTIBODIES THAT BIND HUMAN 17-A1/EpCAM TUMOR
ANTIGEN**

At page 1, line 1, please insert the following paragraph:

This application is a U.S. National Phase Application Under 35 U.S.C. § 371 of International Application No. PCT/WP98/02180 filed April 14, 1998, which claims priority to European Application No. 971061098 filed April 14, 1997.

Please replace the legends for FIGS. 6-9 at page 21 of the specification with the following:

Fig. 6: DNA-and protein-sequence of the human kappa 8 light chain variable region. Numbers indicate the nucleotide (nt) positions, amino acids are presented in single letter code. CDR1 includes nt 70 to nt 102, CDR2 nt 148 to nt 168, CDR3 nt 265 to nt 294 (SEQ ID NO:141).

Fig. 7: DNA-sequence of the human D4.5 heavy chain variable region. Numbers indicate the nucleotide (nt) positions, amino acids are presented in the single letter code. CDR1 includes nt 91 to nt 105, CDR2 nt 148 to nt 198, CDR3 nt 292 to nt 351. The border between the heavy chain variable region and the CH1 domain of the Ig delta constant region is located between nt 382 and 383 with the delta constant region protein sequence starting at nt 384 (SEQ ID NO:143).

Fig. 8: DNA-sequence of the human D7.2 heavy chain variable region. Numbers indicate the nucleotide (nt) positions, amino acids are presented in the single letter code. CDR1 includes nt 91 to nt 105, CDR2 nt 148 to nt 198, CDR3 nt 292 to nt 309. The border between the heavy chain variable region and the CH1 domain of the Ig delta constant region is located between nt 340 and nt 31 with the delta constant region protein sequence starting at nt 343 (SEQ ID NO:145).